glp 1 risk of cancer A new Penn Medicine study more than 110,000 women found that those who took GLP-1 medications were about 30% less likely to develop breast than those who did not. Presented The effect of GLP-1R agonists

Lifestyle is always the first intervention

ND refers to assays that exhibited no detectable activity

It may be relevant when remodeling occurs under metabolic strain GLP-1 use, caloric deficit, or chronic fatigue

As the Mexican government places greater emphasis on standardizing healthcare services and strengthening the management of chronic diseases, we find it especially meaningful that Hanmi's independently developed, Korea's first GLP-1based obesity and metabolic disease treatment, together with our innovative diabetes treatment portfolio, will be able to contribute to improving the health of the Mexican population." Meanwhile, Hanmi completed its regulatory application for efpeglenatide to the Ministry of Food and Drug Safety on December 17, 2025